Thank you. You have found and provided some nice info.
I find it interesting that they characterized it as a "limited competition" product, that they said that there was significant trials that had to take place (they were a little vague on whether trials had to take place prior to approval or distribution, but I assume the former). It was also noteworthy that the they only forecast a 10% market share, but a 30% drop in price (maybe they were conservative on both?). I add a 10% market share (and I think they gave a range that started at 8%), isn't that much, because this is a market that, unusually, is still growing.
Thank you. remember, this company is not about one drug. It is about a few drugs. They must really produce on new products. I have been saying that for 5 years.